Nebivolol induces calcium-independent signaling in endothelial cells by a possible β-adrenergic pathway

Nebivolol is a highly selective beta (1)-adrenoreceptor-blocking agent with a peculiar pharmacodynamic profile. It has peripheral acute vasodilating properties that are mediated by modulation of the endogenous production of nitric oxide. In this study we analyzed the different signaling pathways im plicated in the response of human umbilical vein endothelial cells to nebivolol. Its effect on endothelial transduction pathways was determined by assaying phospholipase C and A(2) activities and cyclic adenosine monophosphate (AMP) production. Variations in intracellular calcium concentration were also measured. Our results showed that nebivolol activates a calcium-independent transduction pathway that implicates an increase in adenylate cyclase and phospholipase A(2) activity. beta (1)- or beta (2)-Adrenoreceptor antagonists do not inhibit the action of nebivolol. However, its action on cyclic AMP production is inhibited by bupranolol, a beta (1-3)-adrenoreceptor antagonist, and S-(-)-cyanopindolol, a selective beta (3)-adrenoreceptor antagonist. Nebivolol also dose-dependently increased nitrite production. This effect was inhibited by bupranolol, suggesting that the possible action of nebivolol on beta (3)-adrenoreceptor is involved in its vasodilating properties. This study suggests that nebivolol could behave as a beta (3)-adrenoreceptor agonist and induce some calcium-independent pathways implicating phospholipase A(2) and adenylate cyclase. This agonistic activity of nebivolol seems to be responsible for its endothelium-dependent vasodilating activity.